Holen Sie sich die Stockscreener-App
89.89
3.46%
3.01
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
Kymera Therapeutics Announces Major Stock Offering - TipRanks
Kymera Therapeutics stock soars 30%. Why investors are excited about its anti-inflammatory drug. - MSN
Kymera Therapeutics raises $602M following positive clinical trial results for lead drug - The Business Journals
Eight biopharmas tap markets for $3.24B in early holiday rally - BioWorld MedTech
JP Morgan Raises Kymera Therapeutics (KYMR) Price Target to $125 - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $125.00 at JPMorgan Chase & Co. - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Up After Analyst Upgrade - MarketBeat
Kymera Therapeutics stock price target raised to $134 from $84 at H.C. Wainwright - Investing.com UK
Avoiding Lag: Real-Time Signals in (KYMR) Movement - news.stocktradersdaily.com
KYMR Expands Common Stock Offering to $602 Million - GuruFocus
JPMorgan Chase & Co. Buys 160,848 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics Prices $602 Million Common Share Offering - marketscreener.com
Kymera Therapeutics prices $602M public offering at $86.00 a share - MSN
Kymera Therapeutics prices $602 million public offering of common stock - Investing.com India
Kymera Therapeutics prices $602 million public offering of common stock By Investing.com - Investing.com Australia
Kymera Therapeutics Announces Pricing of $602 Million Public Offering of Common Stock - Quiver Quantitative
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering - The Manila Times
Kymera Therapeutics announces pricing of upsized $602 million public offering at $86 per share - marketscreener.com
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering | Associated Press | syndication news - Enidnews.com
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering - GlobeNewswire Inc.
B of A Securities Maintains Kymera Therapeutics (KYMR) Buy Recommendation - Nasdaq
Jefferies Raises Price Target for Kymera Therapeutics (KYMR) to - GuruFocus
Kymera Therapeutics (KYMR) Sees Price Target Raised by Citigroup - GuruFocus
Jefferies raises Kymera Therapeutics stock price target to $122 on KT-621 data - Investing.com UK
Kymera (KYMR) Jumps to All-Time High as Eczema Treatment Results Impress - Finviz
Truist Securities Raises Kymera Therapeutics (KYMR) Price Target - GuruFocus
Oppenheimer Raises Kymera Therapeutics (KYMR) Price Target to $120 | KYMR Stock News - GuruFocus
KYMR: Morgan Stanley Raises Price Target to $127, Maintains Over - GuruFocus
Barclays Raises Kymera Therapeutics (KYMR) Price Target Significantly | KYMR Stock News - GuruFocus
Kymera Keeps Rising With More Positive Dupixent-In-A-Pill Data - Citeline News & Insights
KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study - Finviz
Kymera Therapeutics slides after launching $500 million share offering - TradingView
Kymera Therapeutics (KYMR): Piper Sandler Raises Price Target to $125 | KYMR Stock News - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Down on Insider Selling - MarketBeat
HC Wainwright & Co. Elevates Kymera Therapeutics (KYMR) Price Ta - GuruFocus
Kymera Therapeutics (KYMR) Sees Notable Decline in Stock Price - GuruFocus
Kymera stock price target raised to $125 from $98 at Piper Sandler on positive trial data - Investing.com
Oppenheimer Adjusts Kymera Therapeutics PT to $120 From $67, Maintains Outperform Rating - marketscreener.com
Truist Securities Adjusts Kymera Therapeutics PT to $116 From $80, Maintains Buy Rating - marketscreener.com
Kymera Therapeutics (KYMR) Receives Upgraded Price Target from Leerink Partners | KYMR Stock News - GuruFocus
Bank of America Issues Positive Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price - MarketBeat
Kymera Therapeutics: Promising Phase 1b Trial Results and Competitive Edge Drive Buy Rating - TipRanks
Kymera Therapeutics price target raised to $120 from $67 at Oppenheimer - TipRanks
Maven Securities LTD Takes $2.18 Million Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics (KYMR) Receives Raised Price Target from B o - GuruFocus
Morgan Stanley Raises Price Target on Kymera Therapeutics to $127 From $73, Keeps Overweight Rating - marketscreener.com
Kymera Therapeutics stock price target raised to $116 at Wells Fargo on positive trial data - Investing.com Canada
BTIG Maintains Kymera Therapeutics (KYMR) Buy Recommendation - Nasdaq
Oppenheimer raises Kymera Therapeutics stock price target to $120 on promising trial data - Investing.com UK
Kymera Therapeutics CMO Gollob sells $4.37 million in shares By Investing.com - Investing.com South Africa
KYMR: BTIG Raises Price Target and Maintains Buy Rating | KYMR S - GuruFocus
Kymera Therapeutics Insider Sold Shares Worth $8,917,000, According to a Recent SEC Filing - marketscreener.com
Kymera Therapeutics Insider Sold Shares Worth $4,371,833, According to a Recent SEC Filing - marketscreener.com
Kymera Therapeutics stock price target raised to $138 from $75 at BTIG By Investing.com - Investing.com South Africa
10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs - Insider Monkey
Kymera Therapeutics stock price target raised to $138 from $75 at BTIG - Investing.com Canada
Kymera Therapeutics: Surge in Stock Price - StocksToTrade
Kymera readout hints at new era for degraders in immunology - BioCentury
Kymera Therapeutics Inc. (KYMR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 100,000 Shares - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Insider Sells $4,372,051.69 in Stock - MarketBeat
Jeffrey Albers Sells 5,000 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Kymera Therapeutics CMO Gollob sells $4.37 million in shares - Investing.com
Kymera Therapeutics CEO Nello Mainolfi sells $8.92 million in shares By Investing.com - Investing.com Australia
Kymera Therapeutics director Albers sells $448,823 in shares - Investing.com
Kymera Therapeutics CEO Nello Mainolfi sells $8.92 million in shares - Investing.com
Kymera Therapeutics stock hits 52-week high at 90.28 USD By Investing.com - Investing.com South Africa
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):